Kim D. Blickenstaff Joins RMI Board of Directors as an Observer

“We are delighted to have Kim on the team”, said Laura Piccinini CEO of RMI.  “He brings tremendous wisdom and experience building successful medical device companies.”

Mr. Blickenstaff has served as the Chairman of the board of directors of Tandem Diabetes ($5.23 billion market cap) since March 2020. Mr. Blickenstaff previously served as Executive Chairman of the board of directors since March 2019, and on the board of directors since September 2007. Mr. Blickenstaff also previously served as the President and Chief Executive Officer from September 2007 to March 2019. 

Prior to joining Tandem Diabetes, Mr. Blickenstaff served as Chairman and Chief Executive Officer of Biosite Incorporated, or Biosite, a provider of medical diagnostic products, from 1988 until its acquisition by Inverness Medical Innovations, Inc. in June 2007 for $1.68 billion. 

Prior to founding Biosite, he held various finance, operations, research management, sales management, strategic planning and marketing positions with Hybritech Incorporated and Baxter Healthcare. 

Mr. Blickenstaff previously served as a director of Medivation, Inc., a biotechnology company, from 2005 to 2016, until its acquisition by Pfizer for $14 billion, and as a director of DexCom, Inc. (NASDAQ: DXCM; $38 billion market cap), a provider of continuous glucose monitoring systems, from June 2001 to September 2007. Mr. Blickenstaff was recognized as the 2020 Director of the Year by The Corporate Directors Forum for his outstanding performance in the boardroom and behind the scenes.

“I am excited to join the Board at RMI,” said Kim Blickenstaff.   “It is an opportunity to build a new standard of care for respiratory monitoring and improve patient safety in a wide variety of applications.”